Infectious diseases caused by Staphylococcus aureus present a significant clinical and public health problem. S. aureus causes some of the most severe hospital-associated and community-acquired illnesses. Specifically, it is the leading cause of infective endocarditis and osteomyelitis, and the second leading cause of sepsis in the USA. While pathogenesis of S. aureus infections is at the center of current research, many questions remain about the mechanisms underlying staphylococcal toxic shock syndrome (TSS) and associated adaptive immune suppression. Both conditions are mediated by staphylococcal superantigens (SAgs)—secreted staphylococcal toxins that are major S. aureus virulence factors. Toxic shock syndrome toxin-1 (TSST-1) is the SAg responsible for almost all menstrual TSS cases in the USA. TSST-1, staphylococcal enterotoxin B and C are also responsible for most cases of non-menstrual TSS. While SAgs mediate all of the hallmark features of TSS, such as fever, rash, hypotension, and multi-organ dysfunction, they are also capable of enhancing the toxic effects of endogenous endotoxin. This interaction appears to be critical in mediating the severity of TSS and related mortality. In addition, interaction between SAgs and the host immune system has been recognized to result in a unique form of adaptive immune suppression, contributing to poor outcomes of S. aureus infections. Utilizing rabbit models of S. aureus infective endocarditis, pneumonia and sepsis, and molecular genetics techniques, we aim to elucidate the mechanisms of SAg and endotoxin synergism in the pathogenesis of TSS, and examine the cellular and molecular mechanisms underlying SAg-mediated immune dysfunction.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Klein E, et al. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6.
Murdoch DR, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169:463–73.
Fowler VG Jr, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012–21.
Bor DH, et al. Infective endocarditis in the US, 1998–2009: a nationwide study. PLoS ONE. 2013;8:e60033.
Shorr AF, et al. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large US database. Crit Care Med. 2006;34:2588–95.
Wisplinghoff H, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.
Spaulding AR, et al. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013;26:422–47.
Korol E, et al. A systematic review of risk factors associated with surgical site infections among surgical patients. PLoS ONE. 2013;8:e83743.
DeVries AS, et al. Staphylococcal toxic shock syndrome 2000–2006: epidemiology, clinical features, and molecular characteristics. PLoS ONE. 2011;6:e22997.
Bergdoll MS. Monkey feeding test for staphylococcal enterotoxin. Methods Enzymol. 1988;165:324–33.
Giantonio BJ, et al. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol. 1997;15:1994–2007.
Spaulding AR, et al. Vaccination against Staphylococcus aureus pneumonia. J Infect Dis. 2013. doi:10.1093/infdis/jit823.
Schlievert PM. Cytolysins, superantigens, and pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. J Infect Dis. 2009;200:676–8.
Schlievert PM, et al. Staphylococcus aureus exotoxins are present in vivo in tampons. Clin Vaccine Immunol. 2010;17:722–7.
Jaglic Z, et al. Experimental study of pathogenicity of Pasteurella multocida serogroup F in rabbits. Vet Microbiol. 2008;126:168–77.
Leimbach A, et al. Escherichia coli as an all-rounder: the thin line between commensalism and pathogenicity. Curr Top Microbiol Immunol. 2013;358:3–32.
Schlievert PM, et al. Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob Agents Chemother. 2008;52:4448–54.
CDC (2011) Toxic shock syndrome (other than Streptococcal) (TSS).
Gaventa S, et al. Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis. 1989;11(Suppl 1):S28–34.
Jain A, Daum RS. Staphylococcal infections in children: Part 3. Pediatr Rev. 1999;20:261–5.
Jain A, et al. Staphylococcal infections in children: Part 2. Pediatr Rev. 1999;20:219–27.
Jain A, Daum RS. Staphylococcal infections in children: Part 1. Pediatr Rev. 1999;20:183–91.
Davis JP, et al. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 1980;303:1429–35.
Schlievert PM. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet. 1986;1:1149–50.
Schlievert PM, et al. Purification and physicochemical and biological characterization of a staphylococcal pyrogenic exotoxin. Infect Immun. 1979;23:609–17.
Schlievert PM, et al. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis. 1981;143:509–16.
Stich N, et al. Staphylococcal superantigen (TSST-1) mutant analysis reveals that t cell activation is required for biological effects in the rabbit including the cytokine storm. Toxins (Basel). 2010;2:2272–88.
Gorbach SL. Microbiology of the gastrointestinal tract. In: Baron S, editor. Medical microbiology. Chap. 95, 4th ed. Galveston, TX: University of Texas Medical Branch at Galveston; 1996.
Varga M Textbook of Rabbit Medicine. Butterworth-Heinemann, Elsevier Health Sciences.
Sugiyama H, et al. Enhancement of bacterial endotoxin lethality by staphylococcal enterotoxin. J Infect Dis. 1964;114:111–8.
Schlievert PM, Watson DW. Biogenic amine involvement in pyrogenicity and enhancement of lethal endotoxin shock by group A streptococcal pyrogenic exotoxin. Proc Soc Exp Biol Med. 1979;162:269–74.
Schlievert PM. Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect Immun. 1982;36:123–8.
Duranthon V, et al. On the emerging role of rabbit as human disease model and the instrumental role of novel transgenic tools. Transgenic Res. 2012;21:699–713.
Peng X. Transgenic rabbit models for studying human cardiovascular diseases. Comp Med. 2012;62:472–9.
Lee PK, et al. Fluid replacement protection of rabbits challenged subcutaneous with toxic shock syndrome toxins. Infect Immun. 1991;59:879–84.
Kim YB, Watson DW. A purified group A streptococcal pyrogenic exotoxin. Physiochemical and biological properties including the enhancement of susceptibility to endotoxin lethal shock. J Exp Med. 1970;131:611–22.
Priest BP, et al. Treatment of toxic shock syndrome with endotoxin-neutralizing antibody. J Surg Res. 1989;46:527–31.
Dinges MM, Schlievert PM. Comparative analysis of lipopolysaccharide-induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. Infect Immun. 2001;69:7169–72.
Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology. 2010;52:1829–35.
Schlievert PM, et al. Inhibition of ribonucleic acid synthesis by group A streptococcal pyrogenic exotoxin. Infect Immun. 1980;27:542–8.
Canonico PG, Van Zwieten MJ. Swelling of mitochondria from rabbit liver induced by staphylococcal enterotoxin B. J Infect Dis. 1971;124:372–8.
Stone RL, Schlievert PM. Evidence for the involvement of endotoxin in toxic shock syndrome. J Infect Dis. 1987;155:682–9.
Chu MC, et al. Growth of toxic shock syndrome toxin 1-producing, tryptophan-requiring strains of Staphylococcus aureus associated with the presence of Escherichia coli. Rev Infect Dis. 1989;11(Suppl 1):S101–3.
Chow AW, et al. Vaginal colonization with Staphylococcus aureus, positive for toxic-shock marker protein, and Escherichia coli in healthy women. J Infect Dis. 1984;150:80–4.
Rossi RJ, et al. Staphylococcal enterotoxins condition cells of the innate immune system for Toll-like receptor 4 stimulation. Int Immunol. 2004;16:1751–60.
Wheeler MD. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Res Health. 2003;27:300–6.
Fast DJ, et al. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun. 1989;57:291–4.
Luhm J, et al. One-way synergistic effect of low superantigen concentrations on lipopolysaccharide-induced cytokine production. J Interferon Cytokine Res. 1997;17:229–38.
Beezhold DH, et al. Endotoxin enhancement of toxic shock syndrome toxin 1-induced secretion of interleukin 1 by murine macrophages. Rev Infect Dis. 1989;11(Suppl 1):S289–93.
Beezhold DH, et al. Synergistic induction of interleukin-1 by endotoxin and toxic shock syndrome toxin-1 using rat macrophages. Infect Immun. 1987;55:2865–9.
Chen X, et al. Endotoxin exacerbates immunologically induced liver injury in cooperation with interferon-gamma. Inflamm Res. 2000;49:571–7.
Keane WF, et al. Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. Am J Pathol. 1986;122:169–76.
Callahan JE, et al. Stimulation of B10.BR T cells with superantigenic staphylococcal toxins. J Immunol. 1990;144:2473–9.
Choi Y, et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med. 1990;172:981–4.
Fraser JD. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature. 1989;339:221–3.
Scholl PR, et al. Staphylococcal enterotoxin B and toxic shock syndrome toxin-1 bind to distinct sites on HLA-DR and HLA-DQ molecules. J Immunol. 1989;143:2583–8.
White J, et al. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell. 1989;56:27–35.
Frederick DM, et al. Fatal disseminated herpes simplex virus infection in a previously healthy pregnant woman. A case report. J Reprod Med. 2002;47:591–6.
Cockerill FR, et al. Molecular, serological, and clinical features of 16 consecutive cases of invasive streptococcal disease. Southeastern Minnesota streptococcal working group. Clin Infect Dis. 1998;26:1448–58.
Saha DC, et al. Lipopolysaccharide- and superantigen-modulated superoxide production and monocyte hyporesponsiveness to activating stimuli in sepsis. Shock. 2012;38:43–8.
Vergeront JM, et al. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis. 1983;148:692–8.
Poindexter NJ, Schlievert PM. Suppression of immunoglobulin-secreting cells from human peripheral blood by toxic-shock-syndrome toxin-1. J Infect Dis. 1986;153:772–9.
Spaulding AR, et al. Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Vaccine. 2012;30:5099–109.
Kansal R, et al. Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome. J Clin Immunol. 2007;27:327–38.
Conflict of interest
None of the authors have conflicts of interest to declare.
Katarina Kulhankova and Jessica King have contributed equally to this work.
About this article
Cite this article
Kulhankova, K., King, J. & Salgado-Pabón, W. Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Immunol Res 59, 182–187 (2014). https://doi.org/10.1007/s12026-014-8538-8
- Staphylococcal toxic shock syndrome
- Staphylococcus aureus